期刊文献+

微小RNA-133在慢性心力衰竭患者血清中表达及与心肌重构和心功能的相关性 被引量:16

Expression of miR-133 in the serum of patients with chronic heart failure and its correlation with myocardial remodeling and cardiac function
在线阅读 下载PDF
导出
摘要 目的探讨微小RNA-133在慢性心力衰竭(CHF)患者血清中表达及与心肌重构和心功能相关性。方法选取CHF患者136例,根据美国NYHA分级标准分为:Ⅰ-Ⅱ级45例、Ⅲ级53例、Ⅳ级38例;同期,从体检中心选取健康者50例作为对照组。所有研究对象均行超声心动图检查,检测血清中N末端B型钠肽原(NT-pro BNP)水平和血清中miR-133表达。结果CHF患者血清NT-pro BNP水平、miR-133a和miR-133b表达量均高于对照组,Ⅳ级患者血清NT-pro BNP水平、miR-133a和miR-133b表达量均高于Ⅲ级和Ⅰ-Ⅱ级,且Ⅲ级均高于Ⅰ-Ⅱ级,差异有统计学意义(P〈0.05);CHF患者左室舒张末内径(LVEDD)、左心房内径(LAP)、左心室后壁厚度(LVPW)和左室质量指数(LVMI)均较对照组增加,而左室重构指数(LVRI)、心输出量(CO)和左室射血分数(LVEF)均较对照组减少,差异有统计学意义(P〈0.05),Ⅰ-Ⅱ级患者LAP、LVPW和LVMI均低于Ⅲ级和Ⅳ级,且Ⅲ级均低于Ⅳ级,LVRI、CO和LVEF均高于Ⅲ级和Ⅳ级,且Ⅲ级均高于Ⅳ级,差异有统计学意义(P〈0.05);Pearson相关分析显示,CHF患者血清中miR-133a表达量与NT-pro BNP、LAP、LVPW和LVMI呈正相关(r=0.801、0.620、0.346和0.313,P〈0.05),而与CO和LVEF呈负相关(r=-0.335和-0.523,P〈0.05),血清中miR-133b表达量与NT-pro BNP、LAP、LVPW和LVMI呈正相关(r=0.732、0.593、0.371和0.266,P〈0.05),而与LVRI、CO和LVEF呈负相关(r=-0.194、-0.260和-0.543,P〈0.05)。结论 miR-133a和miR-133b在CHF患者血清中表达量升高,与心肌重构和心脏功能密切相关。 Objective To investigate the expression of miR-133 in the serum of patients with chronic heart failure( CHF) and its correlation with myocardial remodeling and cardiac function. Methods A hundred and thirty-six cases of patients with CHF were selected,and were assigned into different groups according to American NYHA classification standards:Ⅰ-Ⅱgrade 45 cases,Ⅲ grade 53 cases and Ⅳ grade 38 cases. During the same period,50 cases of health were selected as the control group. All subjects took echocardiographic examination. The levels of N-terminal B-type natriuretic peptide( NT-pro BNP) and miR-133 were detected. Results The serum levels of NT-pro BNP and expression levels of miR-133 a and miR-133 b in patients with CHF were higher than the control group; the serum levels of NT-pro BNP and expression levels of miR-133 a and miR-133 b in Ⅳ grade patients were higher than Ⅲ grade andⅠ-Ⅱgrade,and Ⅲ grade were higher thanⅠ-Ⅱgrade. The differences were statistically significant( P〈0. 05). The LVEDD,LAP,LVPW and LVMI in patients with CHF were increased,while LVRI,CO and LVEF were decreased compared with the control group. The differences were statistically significant( P〈0. 05). The LAP,LVPW and LVMI inⅠ-Ⅱgrade patients were lower than Ⅲ grade and Ⅳ grade,and Ⅲ grade were lower than Ⅳ grade; LVRI,CO and LVEF were higher than Ⅲ grade and Ⅳ grade,and Ⅲ grade were higher than Ⅳ grade. The differences were statistically significant( P〈0. 05). Pearson correlation analysis showed that the expression levels of miR-133 a in patients with CHF were positively correlated with NT-pro BNP,LAP,LVPW and LVMI( r = 0. 801,0. 620,0. 346 and 0. 313,P〈0. 05),while were negatively correlated with CO and LVEF( r =- 0. 335 and- 0. 523,P〈0.05); the expression levels of miR-133 b in patients with CHF were positively correlated with NT-pro BNP,LAP,LVPW and LVMI( r = 0. 732,0.593,0. 371 and 0. 266,P〈0. 05),while were negatively correlated with LVRI,CO and LVEF( r =- 0. 194,- 0. 260 and- 0. 543,P〈0. 05).Conclusions The expression levels of miR-133 a and miR-133 b in serum of patients with CHF were increased,which were closely related with myocardial remodeling and cardiac function.
作者 张雪莲 原芳
出处 《安徽医药》 CAS 2016年第10期1879-1882,共4页 Anhui Medical and Pharmaceutical Journal
基金 河南省科技发展计划项目(142102310421)
关键词 心力衰竭 微RNAS 心室重构 心脏功能试验 超声心动描记术 聚合酶链反应 Heart failure MicroRNAs Ventricular remodeling Heart function tests Echocardiography Polymerase chain reaction
  • 相关文献

参考文献2

二级参考文献88

  • 1Barrel DP. MicroRNAs: genomics, biogenesis, mechanism, and func- tion[J]. Cell, 2004, 116 (2): 281-297.
  • 2Calin GA, Croce CM. MicroRNA signatures in human cancers [J]. Nat Rev Cancer, 2006, 6( 11 ): 857-866.
  • 3Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14[J]. Cell, 1993, 75(5): 843-854.
  • 4Farazi TA, Spitzer JI, Morozov P, et al. miRNAs in human cancer[J]. J Pathol, 2011, 223(2): 102-115.
  • 5van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles[J]. Nat Rev Drug Discov, 2012, 11 ( 11 ): 860-872.
  • 6O'Connell RM, Rao DS, Chaudhuri AA, et al. Physiological and pathological roles for mieroRNAs in the immune system[J]. Nat Rev Immunol, 2010, 10(2): 111-122.
  • 7Rodriguez A, Griffiths-Jcnes S, Ashurst JL, et al. Identification of mammalian mieroRNA host genes and transcription units [J]. Genome Res, 2004, 14( 10A): 1902-1910.
  • 8Cullen BR. Transcription and processing of human mieroRNA pre- cursors[J]. Mol Cell, 2004, 16(6): 861-865.
  • 9Li Z, Rana TM. Molecular mechanisms of RNA-triggered gene si- lencing machineries[J]. Ace Chem Res, 2012, 45(7): 112241131.
  • 10Hutvaguer G, Zamore PD. A microRNA in a multiple-turnover RNAi enzyme complex[J]. Science, 2002, 297 (5589): 2056-2060.

共引文献5

同被引文献141

引证文献16

二级引证文献226

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部